1Sudoh T,Kang, awa K,Minamino N,et al. A new natriuretie peptide in porcine brain[J]. Nature, 1988,322 ( 6159 ) :78 - 81.
2Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure[J]. Endocr Rev,2003,24 (3) :341 - 356.
3Iwanaga Y, Nishi I, Furuichi S, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure:comparison between systolic and diastolic heart failure[J]. J Am Coll Cardiol,2006,47 (4) :742 - 748.
4Koller K J, Goeddel DV. Molecular biology of the natriuretic peptides and their receptors[J]. Circulation, 1992,86 (4) : 1081 - 1088.
5Emdin M, Passino C, Clerico A. Natriurefic Peptide assays revisited do we need pro-B-type natriuretic Peptide? [J]. J Am Coll Cardiol,2011,57(12) :1396 - 1398.
6Kemperman H, van den Berg M, Kirkels H, et al. B-type natriuretic peptide(BNP) and N-terminal proBNP in patients with end-stage heart failure supported by a left ventricular assist device [J]. Clin Chem,2004,50(9) :1670 - 1672.
8Gegenhuber A,Mueller T,Firlinger F,et al. Timer course of B-type natriuretic peptide(BNP) and N-terminal pro-BNP changes in patients with decompensated heart failure [J]. Clin Chem, 2004,50 (2) :454 -456.
9Mayer SA, De Lemos JA, Murphy SA, et al. Comparison of B-type natriuretic peptide levels in patients with heart failure with versus without mitral regurgitation[J]. Am J Cardiol,2004,93(8) :1002 - 1006.
10McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction [ J ]. Lancet, 1998, 351 (9095) :9 - 13.
3Yeo KT, Wu AH, Apple FS, et al. Multieenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay[ J]. Clin Chem Acta,2003,338 ( 1 - 2 ) : 107 - 115.
4Cauliez B, Guignery J, Marinier S, et al. Two-year stability of NT-proB- NP in frozen samples using the Roche Elecsys system [J]. Ann Clin Biochem,2008,45 ( Pt 3) :318 -319.
5Seino Y, Ogawa A, Yamashita T, et al. Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evalution of heart failure[J]. Eur J Heart Fail, 2004,6 (3) :295 -300.
6Rothenburger M, Wiehter T, Schmid C, et al. Aminoterminal pro type B natriuretic peptide as a predictive and prognostic marker in patients with chronic heart failure[ J]. J Heart Lung Transplant,2004,23 (10) : 1189 - 1197.
7Emdin M, Passino C, Prontera C, et al. Comparison of brain natriuretic peptide(BNP) and amio-terminal proBNP for early diagnosis of heart failure[J]. Clin Chem,2007,53(7) :1289 -1297.
8Grewal J, Mckelvie RS, Persson H, et al. Usefulness of N-terminal probrain natriuretie peptide and brain natriuretie peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ven- tricular ejection fraction[ J]. Am J Cardiol,200$ ,102(6) :733 -737.
9McDonagh TA, Holmer S, Raymond I, et al. NT-proBNP and the diagnosis of heart failure:a pool analysis of three European epidemiological studies [ J]. Eur J Heart Fail,2004,6 (3) :269 - 273.
10Chen AA, Wood M J, Krauser DG, et al. NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients:results from the ProBNP Investigation of Dyspnea in the Emergeney Department (PRIDE) echocardiographic substudy [J]. Eur Heart J,2006,27 ( 7 ) : 839 - 845.
10Carriere V, Roussel L, Ortega N, et al. IL-33, The IL-l-like cyto- kine ligand for ST2 receptor, is a chromatin-assoeiated nuclear fac- tor in vivo[J]. Proc Natl Acad Sci U S A,2007,104(1): 282-287.
